

Cases from the Community: Investigators Discuss the Optimal Clinical Care of Patients with HER2-Positive Gynecologic Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. For endometrial cancer, HER2 positivity by immunohistochemistry (IHC) requires strong, complete or basolateral/lateral membrane staining in what proportion of cells?
 - a. Higher than 10%
 - b. Higher than 30%**
 - c. 50% or higher
2. What was the approximate objective response rate with trastuzumab deruxtecan (T-DXd) for patients with HER2 IHC 3+ advanced endometrial cancer in the Phase II DESTINY-PanTumor02 study?
 - a. 18%
 - b. 33%
 - c. 54%
 - d. 85%**
3. Which of the following factors is associated with an increased risk of febrile neutropenia in patients receiving T-DXd?
 - a. Age older than 65
 - b. Poor renal and/or liver function
 - c. Cardiovascular disease
 - d. Poor nutritional status
 - e. All of the above**
4. What is the optimal method for assessing HER2 status in patients with advanced endometrial cancer?
 - a. Next-generation sequencing (NGS)
 - b. IHC followed by reflex FISH if IHC is equivocal (2+)**
 - c. Either NGS or IHC with reflex FISH (equally effective)
5. What is the approximate incidence of any-grade nausea associated with T-DXd?
 - a. 15%
 - b. 40%
 - c. 60%
 - d. Higher than 70%**